FDA Wiping Market Of Verboten Sunscreen Formats Following 2016 Warnings
This article was originally published in The Rose Sheet
Consumer access to SPF-infused wipes is shrinking following FDA warning letters last year to companies that have since discontinued cited products, which the agency says are unapproved drugs ineligible for OTC sunscreen drug review. It remains to be seen how the maker of KLENSKIN Shower-On sunscreen products will respond, with its entire business model hanging in the balance.
You may also be interested in...
Following an FDA warning letter in 2016 for an unapproved sunscreen drug product, Diamond Wipes now must answer agency concerns regarding “poor-quality water” used in its manufacturing operations. Both warnings stemmed from inspections in the wake of a 2014 product recall for mold contamination.
Inspections conducted over the past year may have contributed to a wider FDA crackdown on unapproved sunscreen drug products – specifically those in dosage forms deemed ineligible under OTC drug review for inclusion in the sunscreen monograph – with five marketers targeted so far this month with warning letters.
Time and extent applicants seeking GRASE status for UV filters should provide FDA with the kind of clinical safety data used to support approval of chronic-use cutaneous drug products, and nonclinical testing should focus on potential long-term adverse effects, according to newly released draft guidance required from the agency under the Sunscreen Innovation Act. FDA is particularly interested in receiving comments about final formulation safety testing it anticipates requiring under specified monograph conditions.